Skip to main content

Advertisement

Table 1 Distribution of baseline characteristics between right-sided and left-sided metastatic colorectal cancer among 161 patients

From: Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie)

  All (n = 161) Right-sided mCRC (n = 38) Left-sided mCRC (n = 123) p-value
Sex
 Malea 103 (64) 26 (68) 77 (63) 0.646
 Femalea 58 (36) 12 (32) 46 (37)
Median age at diagnosis of metastatic disease     
 (range)a 65 (35–85) 67.5 (35–85) 65 (39–84) 0.127d
Grading 161 (100)  
 I 1 (1) 0 (0) 1 (1) 1.000
 IIa 102 (63) 25 (66) 77 (63)
 IIIa 51 (32) 13 (34) 38 (31)
 Not available 7 0 7
Detection of metastases
 Synchronousa 108 (67) 28 (74) 80 (65) 0.427
 Metachronousa 53 (33) 10 (26) 43 (35)
Histologic subtype
 Non-mucinousa 143 (89) 30 (79) 113 (92) 0.038c
 Mucinousa 18 (11) 8 (21) 10 (8)
Location of first metastases
 Liverb,e 108 (67) 28 (74) 80 (65) 0.427
 Lungb,e 51 (32) 7 (18) 44 (36) 0.070
 Peritoneumb,e 31 (19) 9 (24) 22 (18) 0.578
 Otherb,e 38 (24) 11 (29) 27 (22) 0.503
 Liver and peritoneumb,e 15 (9) 4 (11) 11 (9) 0.754c
Liver-limited metastases
 Yesa 59 (37) 14 (37) 45 (37) 1.000
 Noa 102 (63) 24 (63) 78 (63)  
First-line systemic therapy
 Anti-VEGF basedb 79 (49) 20 (53) 59 (48) 0.751
 Bevacizumab 76 20 56  
 Aflibercept 3 0 3  
 Anti-EGFR basedb 30 (19) 8 (21) 22 (18) 0.781
 Cetuximab 20 5 15  
 Panitumumab 10 3 7  
 Chemotherapy onlyb 41 (25) 9 (24) 32 (26) 0.940
 No systemic therapy 11 (7) 1 (2) 10 (8)  
Metastasectomy with curative intent
 Yesa 36 (22) 5 (13) 31 (25) 0.197
 Noa 123 (77) 32 (84) 91 (74)
 Not available 2 (1) 1 (3) 1 (1)
Chemotherapy backbone
 Oxaliplatina 91 (56) 24 (63) 67 (55) 0.712
 Irinotecana 40 (25) 9 (23) 31 (25)
 5-FU/Capecitabine monoa 19 (12) 4 (11) 15 (12)
 No Chemotherapya 11 (7) 1 (3) 10 (8)
  1. Percentage in brackets, aincluded categories, bnumber of patients in individual categories versus all other patients in the respective group, ctwo-sided Fisher’s exact test, dtwo-sided Wilcoxon rank-sum test, emultiple designations are possible, Χ2-test with Yates’ correction in all other cases